DC Chemicals

DC67605 · Updated 28 October 2026

PyCB lipid

Literature evidence · DC67605

Formulation & Performance

The optimized ThrCo formulation and its immune-cell, repeat-dose and tumour-model results are presented separately from the earlier screening mixtures.

Reported performance refers to the complete research formulation and the stated experimental model.

Formulation components and molecular-weight conversion

ComponentDC Chemicals productMolecular weightMolar ratioMass at 1 µmol total lipid (mg)
ALC-0315DC42537766.2735.60.272792
PyCB lipidDC67605929.4244.40.412662
DSPCDC57005790.15200.158030

ALC-0315/PyCB/DSPC = 35.6:44.4:20 mol%. Source: Supplementary Materials, optimized ThrCo LNP composition (p. 3). This formulation contains neither cholesterol nor PEG lipid. N/P and lipid:RNA mass ratio were not established; neither is inferred from the molar composition.

Component mass calculator

Prefilled proportions follow the source specified above. Molecular weights and ratios are editable. Results are calculated, not measured study data. No N/P or RNA dose is inferred.

ComponentMWMolar ratioMass (mg)Mass %
ALC-0315——
PyCB lipid——
DSPC——

Formulation selection and particle measurements

Experiment / parameterStudy conditionsResult / interpretation
Optimized compositionThree-component ThrCo LNP35.6:44.4:20 mol%; use this final composition rather than ambiguous labels in the earlier screen.
Size, PDI and loadingMain Fig. 2; Supplementary Fig. S3Comparative particle and encapsulation data are plotted. Exact final values are not transcribed from graph heights.
Laboratory comparatorALC-0315/DSPC/cholesterol/DMG-PEG2000, 50:10:38.5:1.5The authors describe this as a BNT162b2 LNP comparator; it is a laboratory formulation and is not the licensed vaccine product.

Splenic expression and cell delivery

Experiment / parameterStudy conditionsResult / interpretation
Luciferase expressionIV mouse reporter experiments; main Fig. 2 and Fig. S6Authors report 4.5-fold higher splenic signal than the laboratory ALC-0315 comparator and >40-fold higher signal than the 18PA formulation.
Benchmark imaging conditionsSupplementary Fig. S60.25 mg/kg luciferase mRNA; imaging 6 h after IV administration.
Functional reporter deliveryCre mRNA in Ai14 reporter mice; main Fig. 3Splenic dendritic cells and macrophages showed reporter activation. This is Cre-mediated recombination, not a CAR-T or Cas9 editing result.

Antigen response and repeat administration

Experiment / parameterStudy conditionsResult / interpretation
Antigen-specific CD8 T cellsOVA mRNA, 5 µg/mouse IV on days 0, 7 and 14; assessed day 17; n = 3Tetramer-positive CD8 T cells: 9.06% for ThrCo, 3.96% for the laboratory comparator and 0.57% for PBS (Fig. 4D,E).
Repeated deliveryTwo weekly EGFP-mRNA doses followed by luciferase mRNA; 5 µg/mouse; final imaging at 24 hSplenic expression was better retained than with the PEG-containing comparator (Fig. 4F–I). This does not establish indefinite repeat-dose performance.

Tumour-model evidence

Experiment / parameterStudy conditionsResult / interpretation
B16F10-OVA lung metastasis model15 µg OVA mRNA/mouse on days 1, 6 and 11; endpoint day 21The ThrCo group had no detectable lung nodules at the reported endpoint (Fig. 5A–C).
InterpretationAntigen-defined mouse tumour modelThe result is specific to this vaccination schedule and model; it is not evidence of universal tumour eradication or human efficacy.

Tolerability and storage

Experiment / parameterStudy conditionsResult / interpretation
Liver chemistryIV mRNA at 1 or 5 mg/kg; 24 h; Fig. 2N–QALT/AST were evaluated; no significant elevation was reported at 1 mg/kg. The higher-dose comparison does not establish chronic safety.
HemolysisMain Fig. 3P,QThe formulation showed low hemolysis under the tested physiological-pH conditions; this endpoint does not replace systemic toxicology.
Short-term storageSupplementary Fig. S5D–GReporter activity was evaluated after 4°C for 48 h, −80°C for one week and 37°C for 24 h. These are formulation experiments, not the isolated lipid shelf life.

Original study figures

Splenic delivery, repeat dosing and tumour outcomes: Figures 2–5 — Original source figures.

References and source locations

  1. Zhao Y, et al. Replacing cholesterol and PEGylated lipids with zwitterionic ionizable lipids in LNPs for spleen-specific mRNA translation. Science Advances 11, eady6460 (2025). DOI: 10.1126/sciadv.ady6460.
  2. Full text and Supplementary Materials: composition p. 3; Figs. S3, S5 and S6; main Figs. 2–5.